Drug reference

pacritinib

JAK2 inhibitor · Immunosuppressant

JAK2 inhibitorImmunosuppressant

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Not yet extracted

Indications

myelofibrosisrheumatoid arthritispsoriatic arthritisulcerative colitispolycythemia veragvhdankylosing spondyloarthritisallergic dermatitisatopic dermatitis

Contraindications

patients at high risk of pulmonary embolism
nonuse during breastfeeding
concurrent use of live vaccines

Side effects

Common

thrombocytopeniaanemianeutropeniaincreased risk of infections (upper respiratory, sinus, common cold, hepatitis c virus)

Serious

increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death
higher rate of all-cause mortality, including sudden cardiovascular death
higher rate of certain cancers
higher rate of thrombosis, cardiovascular death, myocardial infarction, and stroke